F10 and cancer: ,25 In the recently updated American Society of Clinical Oncology (ASCO) clinical guideline of 2023 for patients with cancer, the direct factor Xa inhibitors, apixaban and rivaroxaban, were added as options for extended thromboprophylaxis after cancer surgery.26